In this study, it was found that Lib M can effectively alleviate the symptoms of colitis in the DSS-induced UC mouse model, indicating that Lib M has a reasonable therapeutic prospect as a UC drug targeting NLRP3 (Fan et al., 2020). The gene discussed is NLRP3; the disease is colitis.